Clinical Trial Detail

NCT ID NCT02939651
Title A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Namrata Vijayvergia
Indications

neuroendocrine tumor

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.